ArticleResearch square2025
Polychlorinated biphenyl Endocrine Disruptor Alters Estrogen Receptor beta-Mediated Epigenetic Regulation, Promoting Endometriosis.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
9 authors.
Funding
Abstract
Background: Endometriosis is a pathological condition characterized by the ectopic proliferation of endometrial cells, resulting in chronic pelvic pain and infertility. Exposure to endocrine-disrupting chemicals (EDCs) has been implicated in the development and progression of endometriosis; however, the underlying mechanisms remain largely unclear. Among these EDCs, elevated levels of polychlorinated biphenyl-126 (PCB-126) have been strongly associated with endometriosis. Yet, how PCB-126 exposure contributes to disease progression remains an unresolved and fundamental question. Method: Surgically induced endometriosis mice were randomly assigned to treatment with PCB-126 or vehicle control. To assess the effects of PCB-126 on human endometrial cells, immortalized human endometrial epithelial and stromal cell lines were utilized. To investigate the role of AXL receptor tyrosine kinase (AXL) in PCB-126-mediated endometriosis progression, surgically induced endometriosis mice were randomly treated with an AXL inhibitor. To evaluate the contribution of DNA methyltransferase 3A (DNMT3A) to endometriosis progression, ectopic lesions were generated using endometrium-specific Dnmt3a knockout mice (Dnmt3a Results: In a mouse model of endometriosis, PCB-126 exposure significantly promoted the growth of ectopic lesions by activating the Steroid Receptor Coactivator-1 (SRC-1) isoform/Matrix Metalloproteinase-9 (MMP9)/Estrogen Receptor-β (ERβ) axis, a critical pathway driving disease progression. Additionally, PCB-126 enhanced ERβ activity through upregulation of the AXL/Growth Arrest-Specific 6 (GAS6) signaling pathway within endometriotic lesions. Notably, treatment with BMS-777607, an AXL inhibitor, effectively suppressed ectopic lesion growth in mice. Furthermore, the PCB-126/ERβ axis upregulated Conclusion: PCB-126 promotes endometriosis progression through coordinated activation of the AXL/ERβ/DNMT3A axis, disrupting estrogen-mediated epigenetic regulation and inducing endometriosis-associated immunoinflammatory responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.